Skip to content
Menu

Cryoport, Inc. CYRX

Full chart Compare
Set alert

Price alert · CYRX

All alert types
19.05 USD -0.50 (-2.56%)

Regular-session close

19.05 0.00 0.00%

After hours · Nov 20, 4:01 PM ET

18.83 Day range 19.45
7.61 52-week range 21.78
YTD
+98.44%
1 year
+127.60%

5D +0.43 (+2.18%)

19.5020ThuFriMonTueWed20.17
Market cap
964.87M
Revenue (ttm)
192.44M
Profit margin
-21.46%
EPS (ttm)
-0.90
Shares out
50.65M
Forward P/E
-38.54
YTD return
+98.44%
1-year return
+127.60%
50-day average
17.60
200-day average
13.81
Volume
814.78K
Avg volume
847.14K
Open
19.17
Previous close
19.55
Day's range
18.83 – 19.45
52-week range
7.61 – 21.78
Beta
1.87
Analysts
Strong Buy
Price target
22.33 (+17.2%)
Earnings date
Mar 2, 2027

Key statistics

Enterprise value
887.54M
PEG ratio
62.13
Price / sales
5.31
Price / book
2.35
Revenue growth
13.50%
Free cash flow
-10.91M
Total cash
393.08M
Total debt
231.51M
Return on equity
-7.44%
Short % of float
8.26%

Fundamental scorecard

7 of 25 checks passed on CYRX’s reported financials

ValueGrowthProfitabilityHealthDividend

7of 25 checks passed

  • Value 0 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
CYRX Revenue — quarterly 50.22M
CYRX Net income — quarterly -10.85M
CYRX EPS — quarterly -0.25

Earnings

CYRX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 2, 2027Dec 30, 2026-0.18———
Nov 5, 2026Sep 30, 2026-0.17685-0.25-0.07-41.36%
Aug 6, 2026Jun 30, 2026-0.19333-0.20-0.01-3.45%
May 4, 2026Mar 31, 2026-0.20-0.23-0.03-15.00%
Mar 3, 2026Dec 31, 2025-0.19-0.21-0.02-10.53%
Nov 4, 2025Sep 30, 2025-0.23-0.18+0.05+21.74%

Upgrades / downgrades

CYRX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 6, 2026KeybancmainOverweightOverweight
Nov 6, 2026NeedhammainBuyBuy
Oct 13, 2026BTIGmainBuyBuy
Oct 1, 2026GuggenheimmainBuyBuy
Sep 18, 2026BTIGreitBuyBuy
Aug 7, 2026GuggenheimmainBuyBuy

About Cryoport, Inc.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network. The company's products include Cryoport Express Shippers; Cryoport Elite; Cryoport Express Cryogenic HV3 Shipping System; Smartpak Condition Monitoring System and Tec4Med, an IoT-based monitoring solutions; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services; MVE Fusion cryogenic system, a self-sustaining cryogenic freezer; and MVE Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.

Sector
Industrials
Industry
Integrated Freight & Logistics
Country
United States

News

Your note

Sign in to keep a note on CYRX — it syncs with the Stock Master app.

Insider holders

CYRX insider holders
InsiderRelationLatest transactionDateShares held
BADDOUR LINDADirectorStock Award(Grant)Jun 4, 202668,099
HANCOCK DANIEL MDirectorSaleNov 8, 202669,052
HARIRI ROBERT JDirectorStock Award(Grant)Jun 4, 202661,625
MANDALAM RAMKUMARDirectorSaleJun 7, 202667,894
SAWICKI MARK WOfficerSaleNov 9, 202692,356
SHELTON JERRELL WILSONChief Executive OfficerSaleAug 10, 20261,201,810

Institution ownership

CYRX institution ownership
Holder% heldSharesValueReported
Blackrock Inc.7.80%3,954,27579.76MSep 29, 2026
Morgan Stanley5.05%2,558,68651.61MSep 29, 2026
Cadian Capital Management, LP4.77%2,418,94748.79MSep 29, 2026
Vanguard Capital Management LLC4.24%2,147,34343.31MSep 29, 2026
Fred Alger Management, LLC3.33%1,690,72334.10MSep 29, 2026
Millennium Management Llc2.83%1,435,85628.96MSep 29, 2026

Fund ownership

CYRX fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.01%1,523,86830.74MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.53%1,281,41425.85MSep 29, 2026
First Eagle Funds-First Eagle Small Cap Opportunity Fund2.25%1,141,64823.03MJul 30, 2026
ALGER FUNDS-Alger Small Cap Focus Fund2.11%1,068,55421.55MJul 30, 2026
CALAMOS INVESTMENT TRUST/IL-Calamos Timpani Small Cap Growth Fund1.47%742,85614.98MJul 30, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.14%578,05811.66MJun 29, 2026